Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

449 - Nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas

Date

14 Dec 2018

Session

Poster Display session

Presenters

Yuliya Rogacheva

Citation

Annals of Oncology (2018) 29 (suppl_10): x17-x23. 10.1093/annonc/mdy486

Authors

Y. Rogacheva1, M. Popova2, A. Nekrasova2, I. Tsygankov2, K. Lepik2, L. Stelmah2, I. Moiseev2, S. Bondarenko2, N. Mikhaylova3, V. Baykov2, B. Afanasyev2

Author affiliations

  • 1 Hematology, Pavlov First Saint Petersburg State Medical University, 197022 - Saint-Petersburg/RU
  • 2 Raisa Gorbacheva Institute Of Children Oncology, Hematology And Transplantation, First Pavlov State Medical University of Saint-Petersburg, 197022 - Saint Petersburg/RU
  • 3 Raisa Gorbacheva Institute Of Children Oncology, Hematology And Transplantation, First Pavlov State Medical University of Saint-Petersburg, 197022 - Санкт-Петербург/RU
More

Resources

Abstract 449

Background

Nivolumab (nivo) is a salvage option in relapsed/refractory (r/r) Hodgkin lymphoma (HL) and non-Hodgkin lymphoma. Patients with HIV-related lymphoma may benefit not only anticancer activity of nivo, but also from its potential anti-HIV effect [1]. Just a few cases of HIV-related lymphoma treated with nivo were reported [2,3]. We describe a case series of r/r HIV-related lymphoma receiving nivo in First Pavlov State Medical University of Saint-Petersburg.

Methods

Six male patients with r/r HIV-related lymphoma were treated with nivo in 2017. The primary end point was response to therapy, secondary – toxicity, relapse incidence and overall survival (OS) at 12 months. CTCAE v4.03 for the toxicity and immune-related adverse effects have been used. LYRIC criteria for assessing FDG-PET/CT were applied.

Results

The underlying diseases: HL n = 4 (66%) and diffuse large B-cell lymphoma (DLBCL) n = 2 (34%). Median number of prior lines of therapy was 2 (range, 2-3). Three patients received nivo as a bridge to auto-SCT (ASCT). Relapse after ASCT was treated in one patient, two patients didn’t proceed to ASCT. Two patients received nivo as mono, 4 patients in combi with bendamustine and gemcitabine. The median dose of nivo was 1 mg/kg (range, 0,5-1,5 mg/kg), number of nivo doses – 8,5 (range, 2-12). The median of CD4+ was 382 c/mcl (range, 45-490). One patient didn’t receive cART due acute renal failure. Only 5 patients were available for estimating response, one – died before PET/CT was performed. Overall response rate was 100%. Two – partial remission and three (60%) patients had complete metabolic responses. Toxicity according to CTCAE and an immune-related adverse effect was not registered. Relapse of the underlying disease was diagnosed in 2 patients, time to progression were 485 and 266 days. OS was 83,3%. Patient who didn’t receive cART died from undetermined cause. Summary of patients are outlined in the table.Table: 59P

PtsDsAgeHIV loadCD4+ cells/mclcARTNivoN of nivoResponseFollowed therapyOutcomeFollow up
1HL33<40140+mono10CRAuto-HSCTRemission;Alive; 499 days
2HL41<4045+BeGe12PRContinuedRelapse; 485 daysAlive; 506 days
3HL36<40362+mono10PRContinuedRemission;Alive; 528 days
4HL40<40490+BeGe7CRAuto-HSCTRemission;Alive; 427 days
5DLBCL333381410-BeGe2---Died; 45 days
6DLBCL38<40473+BeGeR7CRAuto-HSCTRelapse; 266 daysAlive; 397 days

Pts – patients, Ds – diagnose, HL – Hodgkin lymphoma, DLBCL – diffuse large B-cell lymphoma, BeGeR – bendamustine, gemcitabine, rituximab, Nivo – nivolumab, CR – complete remission, PR – partial remission, auto-HSCT – hematopoietic stem cell transplantation

Conclusions

Overall response rate to nivo in patients with HIV-related lymphomas was 100%, one-year OS – 83,3%. Toxicity and immune-related adverse effects were not registered. Preliminary data provide that nivo is effective and safety treatment option for r/r HIV-related lymphoma.

Editorial acknowledgement

Guihot A, Marcelin AG, Massiani MA, et al. Drastic decrease of the HIV reservoir in a patient treated with Nivolumab for lung cancer. Ann Oncol. -2018.-Vol. 29.-P.517-518

Chang E., Sabichi A.L., Kramer J.R., et al. Nivolumab Treatment for Cancers in the HIV-infected Population. Journal of Immunotherapy. -2018-Vol.41.-P.379–383

Sandoval-Sus J.D., Mogollon-Duffo F., Patel A., et al. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. Journal for ImmunoTherapy of Cancer. -2017-Vol.20.-P.49

Clinical trial identification

Legal entity responsible for the study

Raisa Gorbacheva Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.